Khouyr, Antoine ElWang, LiJoshi, KrutiPatel, CharmiBaşer, OnurHuang, Ahong2019-08-232019-08-232019Patel, C., El, K. A., Huang, A., Wang, L., Baser, O., & Joshi, K. (August 08, 2019). Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis. Advances in Therapy. 1-13.1865-86520741-238Xhttps://doi.org/10.1007/s12325-019-01039-9https://hdl.handle.net/20.500.11779/1129There is limited literature on treatment patterns, healthcare resource utilization (HRU), and costs among patients who transition from once-monthly paliperidone palmitate (PP1M) to once-every-3-month paliperidone palmitate (PP3M) in a real-world setting. Hence, this study compared treatment patterns, HRU, and costs 12-month pre- and post-PP3M transition among Veteran’s Health Administration (VHA) patients with schizophrenia.eninfo:eu-repo/semantics/closedAccessHealthcare costsSchizophreniaMedication adherenceAntipsychotic agentsNeurologyPaliperidone palmitateArticle10.1007/s12325-019-01039-92-s2.0-85070287900